Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal just won a milestone approval for Rezdiffra in treating NASH. NASH presents a massive potential market that could be worth tens of billions of dollars annually.
Biotech Stock Soars on FDA Drug Approval
11:04am, Friday, 15'th Mar 2024
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) stock is taking off today, after the U.S. Food & Drug Administration (FDA) approved the biotech company's drug for the treatment of non-alcoholic steatohepa
Madrigal Pharmaceuticals wins FDA approval for liver disease drug; shares soar
10:51am, Friday, 15'th Mar 2024
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares soared after the biopharmaceutical firm revealed its live disease drug Rezdiffra has won US Food and Drug Administration (FDA) approval. Shares of
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
10:31am, Friday, 15'th Mar 2024
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
10:17am, Friday, 15'th Mar 2024
Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rising higher on Friday after the company got positive news from the Food and Drug Administration (FDA)! The big news here is the FDA granting acceler
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
06:21pm, Thursday, 14'th Mar 2024
The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
04:44pm, Thursday, 14'th Mar 2024
Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to treat a severe liver disease known as MASH.
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
05:52am, Saturday, 09'th Mar 2024
Madrigal Pharmaceuticals could be days away from winning its first FDA approval. Regeneron Pharmaceuticals expects several key regulatory decisions this year.
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
06:03am, Tuesday, 05'th Mar 2024
Madrigal Pharmaceuticals may soon get its first regulatory approval. If it happens, it will become the first and only player in a large market.
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
05:43am, Friday, 23'rd Feb 2024
Madrigal Pharmaceuticals is close to a key regulatory approval that could send its stock price soaring. However, there are important issues with the company that savvy investors will consider.
Analysts see over 50% gains in these 2 mid-cap biotech stocks
09:10am, Wednesday, 14'th Feb 2024
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatmen
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:30pm, Wednesday, 03'rd Jan 2024
CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
Huge Warren Buffett Purchase Highlights Hot Insider Buying
09:49am, Saturday, 16'th Dec 2023
From executives to beneficial owners, insiders are increasingly stepping up to the buy window as we approach the end of the year.
These 2 Stocks Could Be About to Soar: Are They Buys?
08:45am, Thursday, 07'th Dec 2023
Madrigal aims to offer a treatment in an area where success has eluded many peers. Bluebird Bio is closing in on its third U.S. approval for a gene-editing therapy.
